The lawsuit, filed by Hagens Berman Sobol Shapiro LLP, targets a class period spanning April 16, 2025, to May 4, 2026. Plaintiffs contend that GeneDx executives promised seamless technological synergy and cost efficiencies from the Fabric Genomics unit, despite allegedly harboring knowledge of deep-seated operational disconnects. These claims reached a breaking point on May 4, 2026, when the company revealed a $31.2 million impairment loss tied to the acquisition—erasing roughly 94% of the cash paid for the asset just one year prior.

The market reaction was immediate and severe. Alongside the impairment charge, GeneDx reported missed revenue targets for its testing lines and slashed its full-year 2026 guidance by as much as $75 million. Share prices fell from $67.93 to $34.51, wiping out billions in shareholder value in a single day. Reed Kathrein, the Hagens Berman partner leading the investigation, stated the firm is examining the full scope of management's alleged misrepresentations regarding the company's AI-driven software strategy. Investors who suffered significant losses during the class period have until August 3, 2026, to file for lead plaintiff status.